Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Shas threatens to oppose 2026 state budget over haredi food-voucher exclusion - 2Scientists find evidence that an asteroid contains tryptophan
- 3The Most Vital Crossroads in Olympic History
- 4Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- 5Hezbollah field commander killed in IDF strikes in Beirut
- Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- The Golden Globes gift bag has nearly $1 million worth of swag for some winners and presenters. What's in it?
- Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity.
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Step by step instructions to Advance the Eco-friendliness of Your Kona SUV
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- The most effective method to Explore Moral Situations in Brain research with Your Certification
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
